T 2842/18 (Rituximab for use in a method for treating joint damage/ HOFFMANN-LA ROCHE) of 01.10.2020
- European Case Law Identifier
- ECLI:EP:BA:2020:T284218.20201001
- Date of decision
- 1 October 2020
- Case number
- T 2842/18
- Petition for review of
- -
- Application number
- 06837634.2
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- -
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Method for treating joint damage
- Applicant name
- F. Hoffmann-La Roche AG
Biogen Idec Inc.
Genentech, Inc. - Opponent name
- Richter Gedeon Nyrt.
Boehringer Ingelheim Pharma GmbH & Co. KG/
Boehringer Ingelheim International GmbH
Merck Serono S.A.
European Oppositions Limited
Taylor Wessing LLP (opposition withdrawn)
Hexal AG
Celltrion, Inc.
Mundipharma GmbH
Mundipharma Pharmaceutical s.r.l - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2) (2007)European Patent Convention R 106 (2007)Rules of procedure of the Boards of Appeal Art 13 (2007)Rules of procedure of the Boards of Appeal Art 15(2) (2020)
- Keywords
- Main request, auxiliary request 1: amendments - extension beyond the content of the application as filed (yes);
auxiliary requests 2 and 3: admitted (no);
Obligation to raise objections - objection dismissed - Catchword
- -
- Cited cases
- G 0002/10
Order
For these reasons it is decided that:
The appeal is dismissed.